Skip to main content

Table 3 Comparison of baseline mean for weight, BMI, glucose indices, nesfatin, inflammatory factors, and liver enzymes in overweight/obese patients with non-alcoholic fatty liver disease (NAFLD)

From: Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial

Variables

Nanocurcumin (n = 42) Mean(SD)

Placebo (n = 42) Mean(SD)

P-value

Weight (kg)

86.54(10.98)

86.70(11.15)

0.9*

BMI (kg/m2)

30.67(2.14)

30.75(2.35)

0.9**

Waist circumference (cm)

105.4(6.2)

103.8(6.7)

0.8*

Fat Mass (%)

31.6(6.4)

31.9(4.7)

0.8*

SBP (mmhg)

120.3(4.7)

120.7(4.3)

0.7**

DBP (mmhg)

78.8(4.5)

79.8(4.3)

0.1*

ALT (u/l)

42.8(11.6)

42.1(8.2)

0.7**

AST (u/l)

28.4(6.7)

27.6(7.8)

0.4**

TC (mg/dl)

212.9(18.9)

211.8(21.4)

0.8*

LDL-c (mg/dl)

135.6(17.6)

133.0(20.7)

0.6*

TG (mg/dl)

175.9(70.3)

181.2(65.6)

0.7**

HDL-c (mg/dl)

41.8(5.6)

42.7(5.7)

0.4*

FBS (mg/dl)

89.1(5.4)

89.3(5.8)

0.9*

HbA1c (%)

5.2(0.2)

5.3(0.2)

0.4**

Nesfatin (ng/ml)

1.8(0.5)

1.8(0.4)

0.5*

FBI (μIU/ml)

8.0(0.5)

7.9(0.6)

0.7*

TNF-α (ng/l)

14.7(3.3)

15.1(2.7)

0.2*

IL-6 (ng/l)

7.6(1.5)

7.9(1.5)

0.2*

hs-CRP (mg/l)

5.9(2.5)

5.3(2.5)

0.2**

HOMA-IR (score)

1.77(0.16)

1.75(0.17)

0.7**

QUICKI (score)

0.3505(0.0049)

0.3509(0.0057)

0.7*

  1. *t-test; **Mann-Whitney; ALT alanine transaminase, AST aspartate transaminase, BMI body mass index, FBI fasting blood insulin,FBS fasting blood sugar, HOMA-IR homeostasis model assessment-insulin resistance, hs-CRP high-sensitive C-reactive protein, HDL-C high density lipoprotein-cholesterol, IL-6 interleukin-6, LDL-C low density lipoprotein-cholesterol, QUICKI quantitative insulin sensitivity check index, TC total cholesterol, TNF-α tumor necrosis factor-alpha